What happened
FDA approved tirzepatide to reduce MACE in adults with type 2 diabetes at cardiovascular risk. The claim rests on SURPASS-CVOT against dulaglutide, an active comparator, with an 8% relative reduction. First label expansion for Mounjaro.
What it means for practice
good news for a large group of patients, and the first incretin label written on hard cardiovascular outcomes. The non-diabetic trials are the ones to watch next; if they land, the conversation in longevity clinics changes.
Originally published in The Longevity Medicine Intelligence newsletter (#105).
WRITTEN BYlongevitydocs™ editorsCurated by the longevitydocs™ editorial team from the weekly newsletter
